EYPT EyePoint, Inc.

CIK 0001314102 50 ready 8-Ks latest August 5, 2026, 7:05 AM ET RSS · JSON

Activity: ELEVATED 3 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 5, 2026, 7:05 AM ET

Top materiality 0.85

Event mix other_material ×28 · earnings ×12 · leadership ×4

Sentiment 21 pos · 2 neg · 27 neu

Latest earnings ▼ miss 2026-Q1

Executive change recent →

Recent 8-K filings for EYPT

Highest-materiality recent filing

EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing

November 5, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01

Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).
Cash, equivalents & securities $204M at Sep 30; Oct public offering added $162M net, extending runway into Q4 2027.

Read filing →

August 5, 2026, 7:05 AM ET earnings materiality 0.70 neutral item 2.02 item 9.01

EyePoint Q2 net loss $94.5M ($1.09/sh); cash $180M; LUGANO data expected August 2026

Net loss $94.5M vs $59.4M YoY; revenue $0.5M vs $5.3M.
July 30, 2026, 7:05 AM ET other material materiality 0.65 positive item 8.01 item 9.01

EyePoint completes enrollment in both Phase 3 DME trials of DURAVYU; topline data Q4 2027

Over 480 patients enrolled across COMO and CAPRI trials in five months, ahead of schedule.
July 17, 2026, 4:05 PM ET litigation materiality 0.70 negative item 1.01 item 9.01

EyePoint settles DOJ False Claims Act probe for $4.68M; enters 5-year CIA

Settlement payment of $4,678,981.86 plus 4.25% interest from Jan 28, 2026, due within 14 days.
May 14, 2026, 7:05 AM ET other material materiality 0.75 positive item 8.01 item 9.01

EyePoint receives third positive DSMC recommendation for Phase 3 wet AMD DURAVYU trials

DSMC recommends LUGANO and LUCIA continue without modification; all active treatment-arm patients have received second DURAVYU dose.
May 6, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

EyePoint Q1 net loss $84.8M ($0.99/share); DURAVYU Phase 3 wet AMD data expected mid-2026

Q1 2026 revenue $0.7M vs $24.5M YoY, driven by YUTIQ license deferral; operating expenses $87.9M.
March 20, 2026, 7:59 PM ET litigation materiality 0.60 negative item 7.01

EyePoint files defamation lawsuit against Ocular Therapeutix over false statements about DURAVYU

Complaint filed March 20, 2026 in Middlesex County Superior Court (Massachusetts).
March 4, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases

EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026

Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).
March 2, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027

First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.
January 7, 2026, 6:59 PM ET other material materiality 0.65 neutral item 2.02 item 9.01

EyePoint provides 2026 clinical milestones; ~$300M cash; wet AMD data mid-2026

Phase 3 LUGANO (432 pts) wet AMD top-line data expected mid-2026; LUCIA (475 pts) data to follow.
November 19, 2025, 6:59 PM ET regulatory materiality 0.75 positive item 8.01 item 9.01

EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes

DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.
November 5, 2025, 6:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01

EyePoint Q3 net revenue $1.0M, net loss $59.7M; DURAVYU Phase 3 fully enrolled; $172.5M financing

Q3 2025 total net revenue fell to $1.0M from $10.5M YoY; net loss widened to $59.7M ($0.85/share) vs $29.4M ($0.54/share).
October 17, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01

EyePoint raises ~$150M in public offering to fund DURAVYU clinical development

Pricing: 11M shares at $12.00 each; 1.5M pre-funded warrants at $11.999 each.
October 14, 2025, 7:59 PM ET other material materiality 0.72 positive item 2.02 item 8.01 item 9.01

EyePoint initiates Phase 3 DURAVYU DME program; first patient Q1 2026; dual MOA data

First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) expected Q1 2026; trials enroll ~240 patients each.
August 6, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD

Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.
July 29, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01 item 9.01

EyePoint completes enrollment in both Phase 3 wet AMD trials for DURAVYU; topline data mid-2026

LUCIA enrolled over 400 patients in 7 months; combined LUGANO and LUCIA total over 800 patients.
July 29, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

EyePoint finishes Phase 3 enrollment for DURAVYU in wet AMD; top-line data mid-2026

LUCIA trial enrolled and randomized over 400 patients in seven months; total >800 across both trials.
May 27, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

EyePoint completes Phase 3 LUGANO enrollment for DURAVYU wet AMD; topline data mid-2026

Over 400 patients enrolled/randomized in seven months, one of fastest Phase 3 wet AMD trials.
May 7, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 8.01 item 9.01

EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA

Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.
March 5, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01

EyePoint reports Q4 net loss $41.4M; DURAVYU Phase 3 enrollment ahead of expectations

Q4 net loss $41.4M ($0.64/share) vs $14.1M loss prior year; revenue $11.6M down from $14.0M.
February 5, 2025, 6:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain

DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.
January 13, 2025, 6:59 PM ET other material materiality 0.70 positive item 2.02 item 8.01 item 9.01

EyePoint updates on DURAVYU Phase 3 wet AMD trials enrollment ahead of schedule, Phase 2 DME data expected 1Q 2025

Phase 3 LUGANO trial for DURAVYU in wet AMD one-third enrolled; LUCIA trial tracking ahead of schedule; full enrollment target 2H 2025.
December 4, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

EyePoint dosed first patient in second Phase 3 wet AMD trial (LUCIA); topline data expected 2026

First patient dosed in LUCIA, the second global Phase 3 trial of DURAVYU (vorolanib Durasert E) for wet AMD.
November 7, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing

Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.
October 31, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

EyePoint closes upsized $161M public offering; net proceeds ~$151.1M for DURAVYU development

Closed offering of 14,636,363 shares at $11.00/share, including full underwriter option exercise for 1,909,090 additional shares.
October 28, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02 item 8.01 item 9.01

EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA

DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.
October 24, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

EyePoint doses first patient in Phase 3 LUGANO trial of DURAVYU for wet AMD; LUCIA trial by end 2024, topline 2026

First patient dosed in global Phase 3 LUGANO trial of DURAVYU (vorolanib) for wet AMD; non-inferiority design vs aflibercept.
September 4, 2024, 7:59 PM ET leadership materiality 0.60 positive item 5.02 item 8.01 item 9.01 ◈ executive_change ×3

EyePoint Pharma appoints Fred Hassan to board; directors Guyer, Adamis resign for Merck roles

David Guyer and Anthony Adamis resigned from board effective Sept 3, 2024 due to full-time roles at Merck & Co.
August 7, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

EyePoint reports Q2 net loss of $30.8M; cash runway through DURAVYU Phase 3 topline in 2026

Net loss $30.8M ($0.58/sh) vs $22.9M loss ($0.61/sh) in Q2 2023; total net revenue $9.5M.
June 26, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02 item 8.01 item 9.01

EyePoint announces Phase 3 plans for DURAVYU in wet AMD; positive Phase 2 data

Phase 3 LUGANO and LUCIA trials to enroll ~400 patients each; 2.7mg DURAVYU vs aflibercept; one-year endpoint.
May 8, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

EyePoint Q1 net loss $29.3M; DURAVYU Phase 2 NPDR trial misses primary endpoint; cash runway to 2026

Q1 net loss $29.3M ($0.55/shr) vs $21.2M ($0.56/shr) in Q1 2023; revenue $11.7M (+52% YoY) from YUTIQ deferred revenue.
May 6, 2024, 7:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

EyePoint's DURAVYU misses Phase 2 NPDR primary endpoint; shows reduced progression at 9 months

Primary endpoint not met: 5% (3mg), 0% (2mg) vs 5% control achieved ≥2-step DRSS improvement at 9 months.
March 7, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

EyePoint reports Q4/FY2023 results; positive Phase 2 data for EYP-1901 in wet AMD

Q4 net loss $14.1M ($0.33/sh) vs $43.5M ($1.16/sh) YoY; total net revenue $14.0M (+33%).
March 4, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 8.01 item 9.01

EyePoint names Ramiro Ribeiro as Chief Medical Officer, replaces Dario Paggiarino

Ramiro Ribeiro appointed CMO effective March 1, 2024; succeeds Dario Paggiarino who leaves March 31.
December 8, 2023, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 8.01 item 9.01 ◈ Material Agreements

EyePoint prices $200M public offering at $17/share to fund Phase 3 trials for EYP-1901

Underwritten public offering of 11,764,706 shares priced at $17.00 per share; underwriters exercised option for additional 1,764,705 shares.
December 8, 2023, 6:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

EyePoint closes upsized $230M public offering for wet AMD Phase 3 trials

Closed upsized public offering of 13,529,411 shares at $17.00/share, raising ~$230M gross.
December 4, 2023, 6:59 PM ET other material materiality 0.85 positive item 8.01 item 9.01

EyePoint reports positive Phase 2 DAVIO 2 topline for EYP-1901 in wet AMD; all endpoints met

Both EYP-1901 doses (2mg and 3mg) achieved non-inferiority in BCVA vs aflibercept (difference of -0.3 and -0.4 letters).
November 1, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

EyePoint Q3 net loss narrows to $12.6M; revenue up 52% on YUTIQ royalty recognition

Total net revenue $15.2M (up 52% YoY) driven by $14.4M in royalties from YUTIQ sale.

Executive changes

Appointed

Dr. Reginald Sanders

Director

EYPT · EyePoint, Inc.

Effective: 2025-01-08
Filed: January 8, 2025, 6:59 PM ET

appointed Dr. Reginald Sanders, M.D. to fill the vacancy on the Board, effective January 8, 2025.

Appointed

Fred Hassan

Director

EYPT · EyePoint, Inc.

Effective: 2024-09-03
Filed: September 4, 2024, 7:59 PM ET

the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the "Governance and Nominating Committee"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.

Departed

David R. Guyer

Director

EYPT · EyePoint, Inc.

Effective: 2024-09-03
Successor: Fred Hassan
Filed: September 4, 2024, 7:59 PM ET

On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.

Departed

Anthony P. Adamis

Director

EYPT · EyePoint, Inc.

Effective: 2024-09-03
Successor: Fred Hassan
Filed: September 4, 2024, 7:59 PM ET

On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.

Appointed

Stuart Duty

Director

EYPT · EyePoint, Inc.

Effective: 2023-10-16
Filed: October 16, 2023, 7:59 PM ET

increased the size of the Board to ten (10) members and appointed Stuart Duty to fill the vacancy on the Board, effective October 16, 2023.

Role change

Jay S. Duker

President and Chief Executive Officer

EYPT · EyePoint, Inc.

Effective: 2023-07-10
Filed: July 10, 2023, 7:59 PM ET

the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023

Appointed

Jay S. Duker

Director

EYPT · EyePoint, Inc.

Effective: 2023-07-10
Filed: July 10, 2023, 7:59 PM ET

appointed Dr. Duker to fill the vacancy for the newly created directorship

Role change

Nancy S. Lurker

Executive Vice Chair

EYPT · EyePoint, Inc.

Effective: 2023-07-10
Filed: July 10, 2023, 7:59 PM ET

Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company.

Role change

Jay S. Duker

President and Chief Operating Officer

EYPT · EyePoint, Inc.

Effective: 2023-01-03
Filed: January 6, 2023, 6:59 PM ET

Effective January 3, 2023 (the “Duker Start Date”), the Board of Directors (the “Board”) of the Company appointed Jay S. Duker, M.D., age 64, as the Company's President and Chief Operating Officer.

Appointed

Karen Zaderej

Director

EYPT · EyePoint, Inc.

Effective: 2022-07-11
Filed: July 14, 2022, 7:59 PM ET

increased the size of the Board to eight members and appointed Karen Zaderej to fill the vacancy on the Board, effective immediately.

Appointed

Michael C. Pine

Chief Corporate Development and Strategy Officer

EYPT · EyePoint, Inc.

Effective: 2022-01-10
Filed: January 10, 2022, 6:59 PM ET

On January 10, 2022 (the “ Start Date ”), EyePoint Pharmaceuticals, Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Michael C. Pine, age 46, as the Company’s Chief Corporate Development and Strategy Officer.

Appointed

Jay S. Duker

Chief Operating Officer

EYPT · EyePoint, Inc.

Effective: 2021-11-01
Filed: November 1, 2021, 7:59 PM ET

On November 1, 2021 (the “ COO Start Date ”), EyePoint Pharmaceuticals , Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Jay S. Duker, M.D., age 63, as the Company's Chief Operating Officer.

Earnings & guidance

2026-Q1 EPS reported -$0.99 vs consensus -$0.81 ▼ miss (-21.7%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

21 positive 2 negative 27 neutral

source · EYPT on sec.gov